113847 ⎘
Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1) Dihydrofolate reductase (1.5.1.3)
CRISPR HAVING OR ASSOCIATED WITH DESTABILIZATION DOMAINS
#2COMPOSITIONS AND METHODS FOR CHIMERIC LIGAND RECEPTOR (CLR)-MEDIATED CONDITIONAL GENE EXPRESSION
#3COMPOSITIONS AND METHODS FOR CHIMERIC LIGAND RECEPTOR (CLR)-MEDIATED CONDITIONAL GENE EXPRESSION
#4REGULATION OF GENE EXPRESSION BY APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLICING
#5COMPUTATIONAL METHODS TO IDENTIFY ALLOSTERIC SITES THAT MODULATE ENZYME ACTIVITY
#6TRANSPOSASE FUSION PROTEINS FOR USE IN CELL AND GENE THERAPY
#7ENGINEERING CHEMICALLY INDUCIBLE SPLIT PROTEIN ACTUATORS (CISPA)
#8Compositions and Methods for Cancer Immunotherapy
#9ENGINEERED SPLIT DHFR-BASED METHODS AND SYSTEMS FOR SELECTING CELLS THAT HAVE STABLY ACQUIRED A HETEROLOGOUS POLYNUCLEOTIDE
#10Ribosome-Mediated Incorporation of Peptides and Peptidomimetics
#11DESTABILISING DOMAINS FOR CONDITIONALLY STABILISING A PROTEIN
#12DHFR TUNABLE PROTEIN REGULATION
#13COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION
#14CONTROL OF PROTEIN EXPRESSION WITH TMP-PROTAC COMPOUNDS
#15METHODS OF REGULATING ADENO-ASSOCIATED VIRUS PRODUCTION
#16SYNTHETIC PROTEIN-LEVEL NEURAL NETWORK IN MAMMALIAN CELLS
#17REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY
#18Protein enriched microvesicles and methods of making and using the same
#19TANDEM CD19 CAR-BASED COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#20COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF TRANSCRIPTION
#21Ribosome-mediated incorporation of peptides and peptidomimetics
#22METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES
#23REGULATION OF GENE EXPRESSION BY APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLICING
#24DHFR tunable protein regulation
#25CD40L COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
#26Destabilising domains for conditionally stabilising a protein
#27Small Molecules for Dual Function Positron Emission Tomography (PET) and Cell Suicide Switches
#28SYSTEMS AND METHODS FOR METABOLIC ENGINEERING
#29METHODS AND COMPOSITIONS FOR PREPARING SURFACTANT PROTEIN D (SP-D)
#30METHODS TO ENRICH GENETICALLY ENGINEERED T CELLS
#31DOUBLE KNOCK-OUT CHO CELL LINE METHOD OF ITS GENERATION AND PRODUCING THERAPEUTIC PROTEINS THEREFROM
#32Complement Component 1s (C1s) Deficient Cells for Production of Vaccines and Biopharmaceutical Proteins
#33Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element
#34Programmable protein circuits in living cells
#35CRISPR HAVING OR ASSOCIATED WITH DESTABILIZATION DOMAINS
#36COMPOSITIONS AND METHODS FOR CHIMERIC LIGAND RECEPTOR (CLR)-MEDIATED CONDITIONAL GENE EXPRESSION
#37SYSTEMS AND METHODS FOR ENGINEERING ENZYMES
#38SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLS
#39METHODS, COMPOSITIONS AND CELLS FOR PREPARING SURFACTANT PROTEIN D (SP-D)
#40Protein enriched microvesicles and methods of making and using the same
#41Ribosome-mediated incorporation of peptides and peptidomimetics
#42Compositions and methods for selective protein degradation
#43Compositions and Methods for Cancer Immunotherapy
#44Sensors, methods and kits for detecting NADPH based on resonance energy transfer
#45DHFR tunable protein regulation
#46Regulation of gene expression by aptamer-mediated modulation of alternative splicing
#47DESTABILISING DOMAINS FOR CONDITIONALLY STABILISING A PROTEIN
#48METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES
#49METHODS FOR IMPROVING RECOMBINANT PROTEIN EXPRESSION
#50COMBINATION THERAPY WITH AN ANTI-HYALURONAN AGENT AND THERAPEUTIC AGENT
#51CELL LINE FOR RECOMBINANT PROTEIN AND/OR VIRAL VECTOR PRODUCTION
#52Methods and compositions for preparing surfactant protein D (SP-D)
#53Methods, compositions and cells for preparing surfactant protein D (SP-D)
#54Small molecules for dual function positron emission tomography (PET) and cell suicide switches
#55Selection methods for genetically-modified T cells
#56Expression vector system comprising two selection markers
#57METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES
#58Regulation of gene expression by aptamer-mediated modulation of alternative splicing
#59Ribosome-mediated incorporation of peptides and peptidomimetics
#60CRISPR HAVING OR ASSOCIATED WITH DESTABILIZATION DOMAINS
#61Combination therapy with an anti-hyaluronan agent and therapeutic agent
#62Protein enriched microvesicles and methods of making and using the same
#63Expression vector system comprising two selection markers
#64Chemically defined cell culture media additive
#65METHOD FOR MASS PRODUCTION OF FACTOR VII/VIIA DERIVATIVES
#66Methods for improving recombinant protein expression
#67Methods and products for producing engineered mammalian cell lines with amplified transgenes
#68Methods of making and using chemically self assembled-nanorings
#69Expression vector
#70Puro-DHFR quadrifunctional marker and its use in protein production
#71Combination therapy with an anti-hyaluronan agent and therapeutic agent
#72Methods for improving recombinant protein expression
#73Expression vector system comprising two selection markers
#74Method for Identifying Drug-Sensitizing Antisense DNA Fragments and Use Thereof
#75Application of RNA Interference Targeting dhfr Gene, to Cell for Producing Secretory Protein
#76PURO-DHFR quadrifunctional marker and its use in protein production
#77Application of RNA Interference Targeting DHFR Gene, to Cell for Protein Production
#78Method for making recombinant protein using complementation dependent DHFR mutants
#79Method for identifying drug-sensitizing antisense DNA fragments and use thereof
#80Method for mass production of human pollicle stimulating hormone